Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): Results from the phase III MAVORIC study Meeting Abstract
| Authors: | Kim, Y. H.; Bagot, M.; Pinter-Brown, L.; Rook, A. H.; Porcu, P.; Horwitz, S. M.; Whittaker, S.; Tokura, Y.; Vermeer, M.; Zinzani, P. L.; Sokol, L.; Morris, S.; Kim, E.; Ortiz-Romero, P. L.; Eradat, H.; Scarisbrick, J.; Tsianakas, A.; Elmets, C.; Dalle, S.; Fisher, D. C.; Halwani, A. S.; Poligone, B.; Greer, J. P.; Fierro, M. T.; Khot, A.; Moskowitz, A. J.; Dwyer, K.; Moriya, J.; Humphrey, J.; Hudgens, S.; Grebennik, D. O.; Tobinai, K.; Duvic, M. |
| Abstract Title: | Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): Results from the phase III MAVORIC study |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419402067 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.817.817 |
| Notes: | Meeting Abstract: 817 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
